{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:59:56Z","timestamp":1785373196406,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With guidelines recommending earlier advanced therapy (AT) use after 5\u2010ASA failure for patients with moderately\u2010to\u2010severely active ulcerative colitis (UC), it is important to explore treatment preferences at the point of escalation to first\u2010line AT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A web\u2010based discrete choice experiment (DCE) survey was administered to AT\u2010na\u00efve patients with moderately\u2010to\u2010severely active UC and gastroenterologists in 5 European countries. Treatment attributes included time until symptom improvement, probability of remission and corticosteroid\u2010free remission, risks of cancer, serious infection, and major adverse cardiovascular events (MACE), and mode of administration. Preference weights, relative attribute importance (RAI), and maximum acceptable risk were estimated. A latent class analysis explored preference heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Probability of remission at 1\u00a0year was the most important attribute for patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0514; RAI\u00a0=\u00a045.3%) and gastroenterologists (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0397; RAI\u00a0=\u00a048.5%). Five\u2010year cancer risk was the second most important attribute for patients (RAI\u00a0=\u00a011.8%) and third for gastroenterologists (RAI\u00a0=\u00a010.9%). RAI of MACE was higher for patients than gastroenterologists (10.6% vs. 6.8%). Both were willing to accept risks for increased probability of remission. Latent class analysis identified 4 groups of patients and 2 groups of gastroenterologists with distinct preferences. The relative importance of efficacy was higher compared with safety in latent classes representing 80% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical remission was most important to patients and gastroenterologists, and both were willing to accept some risk in exchange for the benefits of AT. However, some heterogeneity in preferences was observed. To support patient\u2010centered, guideline\u2010concordant care, gastroenterologists should discuss escalation to AT with patients not well\u2010controlled on conventional therapy, incorporating individual preferences through shared decision\u2010making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ueg2.70229","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:36:11Z","timestamp":1780468571000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First\u2010Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries"],"prefix":"10.1002","volume":"14","author":[{"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I University Hospital Schleswig\u2010Holstein Kiel University  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Walsh","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology and Hepatology Unit Oxford University Hospital  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Panattoni","sequence":"additional","affiliation":[{"name":"Precision AQ  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-7268","authenticated-orcid":false,"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7928-5111","authenticated-orcid":false,"given":"Natalie","family":"Land","sequence":"additional","affiliation":[{"name":"Precision AQ  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-8536","authenticated-orcid":false,"given":"Josh","family":"Coulter","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Gahlon","sequence":"additional","affiliation":[{"name":"Precision AQ  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Canada  Kirkland Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Culhane","family":"Maravic","sequence":"additional","affiliation":[{"name":"Precision AQ  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne Inserm 3iHP CHU Clermont\u2010Ferrand Service d\u2019H\u00e9pato\u2010Gastroent\u00e9rologie  Clermont\u2010Ferrand France"},{"name":"Universit\u00e9 Clermont Auvergne Inserm U1071, M2iSH, USC\u2010INRA 2018  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjx009"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.10.001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad120"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae040"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3310\/rhxr5192"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/ceg.s206970"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i26.3092"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_2_12_11_1","unstructured":"B.WheelerandM. J.Braun Package 'Algdesign (2019) 1\u201325."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753831"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.2307\/3146445"},{"key":"e_1_2_12_15_1","volume-title":"Fundamentals of Biostatistics. Eighth Edition","author":"Rosner B.","year":"2015"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae162"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002143\u2010z"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2286191"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae015"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(24)00233\u20104"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjac130"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000437498.14804.50"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1716704"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000001031"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac119"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa257"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00061\u20102"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2033617"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.039"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606910"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.030"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00666\u20108"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215734"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab232.022"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1900750"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ueg2.70229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:27:24Z","timestamp":1785371244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/ueg2.70229"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.70229","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e70229"}}